Apr 04, 2023 / 02:45PM GMT
Operator
You may begin.
Debjit D. Chattopadhyay - Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
All right. Good morning, and thank you for joining us on Guggenheim's Genomic Medicine and Rare Disease conference, day 2. This is the fifth iteration. I am Debjit and I'm one of the covering analysts at Guggenheim. My privilege to welcome Ionis Pharmaceuticals Executive Vice President of Research, Eric Swayze. Good morning, Eric. Thank you for your time today.
Eric E. Swayze - Ionis Pharmaceuticals, Inc. - EVP of Research
Good morning, and thanks for having me on your show. Appreciate being here.
Questions and Answers:
Debjit D. Chattopadhyay - Guggenheim Securities, LLC, Research Division - Senior Analyst of BiotechnologyWell not much of a show, but let's get on with the Q&A then. I mean, obviously, given the depth and breadth of the pipeline and the recent positive - [go over] some panel votes, any key programs you would like -- or the
Trustpilot
